DETAILED TABLE LISTING
====================================================================================================

Total labeled tables: 149

Page   21: Table   1 - lists the approximate
Page   21: Table   1 - Frequencies associated with different types of electromagnetic radiation.
Page   25: Table   2 - MZ recovery fractions at different multiples of T1 times.
Page   27: Table   3 - MXY residual fractions at different multiples of T2 times.
Page   42: Table   4 - International Electrotechnical Commission (IEC) guidelines on SAR.
Page   53: Table   1 - below gives the suscepti-
Page   53: Table   1 - Magnetic susceptibility and density of common materials.
Page   61: Table   2 - gives
Page   61: Table   2 - Force index of common objects.
Page   98: Table   1 - provides a brief overview of properties that change with increasing static mag-
Page   98: Table   1 - Properties that change with increasing static magnetic field strength.
Page  103: Table   2 - gives an overview of safety assessments of passive implants
Page  104: Table   2 - Overview of various implants that have been tested under certain conditions in
Page  114: Table   1 - Comparison of the physical effects of the various fields applied to patients dur-
Page  116: Table   2 - (106-115). In this table, the timing of major increases in field strength has been
Page  117: Table   2 - Historical development of MRI-related static magnetic field strengths (Data
Page  128: Table   3 - Also, the asymptotic limits
Page  128: Table   3 - Magnetic properties of ellipsoids of revolution.
Page  164: Table   1 - Given the range of combinations of
Page  164: Table   1 - Literature results for gradient coil PNS perception thresholds and chronaxies
Page  165: Table   2 - shows a summary of PNS studies using this alternative gradient formulation
Page  165: Table   2 - Literature results for gradient coil PNS perception thresholds and chronaxies
Page  175: Table   1 - MR system-related acoustic noise will interfere with the communication of activation
Page  175: Table   1 - A summary of potential issues with unwanted acoustic noise in fMRI (14). Re-
Page  176: Table   2 - displays a range of sound pressure levels for some typical sources
Page  178: Table   2 - Sound pressure level for some typical sources of acoustic noise.
Page  188: Table   3 - The International Commission on Non-Ionizing Radiation Pro-
Page  188: Table   3 - Occupational noise action values and limits (adapted from reference 80).  Repro-
Page  238: Table   1 - lists local SAR levels required to
Page  238: Table   1 - demon-
Page  238: Table   1 - Athey (53) has shown similar theoretical results
Page  238: Table   1 - Maximum local SAR level for local temperature rise of 1˚Celsius for various
Page  271: Table   1 - BioRef 2021 V10 001-434_Layout 1  12/5/2021  3:22 PM  Page 254
Page  272: Table   1 - Limits to RF exposure in MRI equipment (2). For global exposure or protection
Page  276: Table   2 - provides an overview of
Page  276: Table   2 - Overview of experimental data for core temperature rise in relation to RF energy
Page  280: Table   2 - (estimated 1 clo, room temperature not specified but likely close to 23°C).
Page  309: Table   1 - (3-5, 7, 9, 11, 12,
Page  309: Table   1 - Recommended techniques for managing patients with claustrophobia or emo-
Page  315: Table   1 - should be attempted for these patients before electing to
Page  326: Table   1 - Spontaneous adverse outcomes of pregnancy.
Page  326: Table   2 - Safety of MRI in pregnancy: Non-adverse outcomes in animals.
Page  327: Table   3 - Safety of MRI in pregnancy: Adverse outcomes in animals and human cell cul-
Page  327: Table   4 - Safety of MRI in pregnancy:  Non-adverse outcomes in humans.
Page  328: Table   5 - Currently approved MRI contrast agents.
Page  329: Table   6 - Safety of gadolinium-based MRI contrast agents in pregnancy*.
Page  330: Table   6 - and Table 7.
Page  330: Table   7 - Safety of non-gadolinium-based MRI contrast agents in pregnancy (data from
Page  331: Table   6 - It is predictable that the dissociation of the gadolinium chelate
Page  351: Table   1 - Most acute reactions to GBCAs are mild, self-limiting, and do not require specific
Page  351: Table   1 - Type and severity of acute adverse reactions to gadolinium-based contrast agents
Page  354: Table   2 - Suitable premedication regimens (adapted from Reference 15).
Page  355: Table   3 - Equipment and medications supply list for patient examination room
Page  357: Table   4 - and Table 5, include infor-
Page  358: Table   4 - Management of acute reactions to gadolinium-based contrast agents in adult
Page  360: Table   5 - Management of acute reactions to gadolinium-based contrast agents in pediatric
Page  375: Table   1 - Clinical findings for the diagnosis of nephrogenic systemic fibrosis.
Page  444: Table   1 - It is interesting to note that although the patients in each of
Page  445: Table   1 - Summary of patient screening studies using FMD device technology. All studies
Page  454: Table   1 - summarizes the types
Page  454: Table   1 - Types of patients that may require physiological monitoring and support during
Page  457: Table   2 - List of manufacturers and suppliers of physiological monitors and support de-
Page  461: Table   3 - Recommendations to prevent excessive heating and possible burns in associa-
Page  462: Table   3 - Monitoring Equipment and Support Devices
Page  462: Table   3 - (Continued)
Page  480: Table   1 - and Table 2.
Page  480: Table   2 - Possible MRI-related risks for active implants.
Page  480: Table   1 - Possible MRI-related risks for passive implants.
Page  486: Table   3 - presents techniques that may be used to reduce
Page  486: Table   3 - Techniques to reduce artifacts associated with metallic implants.
Page  494: Table   4 - Guidelines for the management of patients with coronary artery stents
Page  497: Table   5 - Guidelines for the management of patients with heart valve prostheses and annu-
Page  499: Table   6 - In consideration of this, it is often necessary to involve the radiologist whenever
Page  499: Table   6 - Adjusting pulse sequence parameters to lower SAR values.
Page  502: Table   7 - Guidelines for the management of patients with vascular access ports.
Page  517: Table   1 - Potential implant risks associated with MRI and the test performed to character-
Page  538: Table   1 - Qualitative comparison of RF-induced and gradient field-induced heating in terms of the implant
Page  538: Table   2 - Maximum temperature elevation ΔTmax versus position z of a total hip prosthesis made of CoCrMo
Page  539: Table   1 - A graphical illus-
Page  573: Table   1 - Figure 2 also illustrates
Page  574: Table   1 - Potential patient hazards and corresponding test methods.  Each “Clause” or
Page  575: Table   2 - includes a detailed view on one way an
Page  575: Table   2 - List of examples of MRI-related AIMD safety hazards, each of which generates
Page  576: Table   2 - (continued)
Page  577: Table   3 - Evaluation of the AIMDs for MRI Hazards Involves Bench-Top Testing, Modeling,
Page  577: Table   3 - Categorization of MRI safety assessments based on whether or not electromag-
Page  610: Table   1 - lists measured and calculated rises for the three leads in the straight-line path
Page  610: Table   2 - lists measured and calculated tem-
Page  611: Table   1 - Measured and calculated temperature rises for the vagus nerve stimulation
Page  612: Table   2 - Measured and calculated temperature rises for the vagus nerve stimulation lead
Page  619: Table   3 - provide information on electrical skin depths at different fre-
Page  621: Table   3 - Electrical skin depths for medical alloys.  270-Hz is the default (Tier 1) fre-
Page  624: Table   1 - and Table 2 were the same transfer function yields calculated temperature rises
Page  649: Table   1 - summarizes the main characteristics of the four models of the VF.
Page  649: Table   1 - Main characteristics of the four models of the first generation of the Virtual
Page  657: Table   2 - Evaluation of an AIMD for these hazards involves some combination of testing and mod-
Page  657: Table   2 - Potential patient hazards and corresponding test requirements, as described in
Page  677: Table   1 - At our institution, the Johns Hopkins Hospital, we began the process of performing MRI
Page  677: Table   2 - During our in vitro testing of ICDs, we found several pulse generators
Page  678: Table   1 - Clinical studies of MRI in the setting of standard permanent cardiac pacemakers.
Page  679: Table   1 - and Table 2). A noteworthy study is the MagnaSafe Registry, a
Page  679: Table   1 - (Continued)
Page  680: Table   2 - Clinical MRI studies in the setting of standard ICD systems.
Page  681: Table   2 - (Continued)
Page  685: Table   3 - (39).
Page  686: Table   3 - Center for Medicaid & Medicare Services (CMS) Guidelines for 1.5 T MRI fa-
Page  693: Table   1 - Summary of MRI case reports and studies involving patients with non-MR Con-
Page  694: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  695: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  696: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  697: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  698: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  699: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  700: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  701: Table   1 - (Continued) Summary of MRI examinations involving patients with cardiac
Page  706: Table   2 - Summary of MRI examinations involving patients with abandoned pacing leads.
Page  730: Table   1 - (3-7, 9, 14-28). Importantly, each of these variables must be taken into
Page  732: Table   1 - Important variables that impact MRI-related heating of a medical implant.
Page  740: Table   2 - Head-Only Deep Brain Stimulation (DBS) System, Activa SC Model 37602,
Page  741: Table   3 - Full-Body Deep Brain Stimulation (DBS) System, Model B35200, Medtronic,
Page  742: Table   4 - Full-Body Vercise Gevia Deep Brain Stimulation (DBS) System, Boston Scien-
Page  743: Table   5 - Spinal Cord Stimulation Systems
Page  744: Table   5 - Responsive Neurostimulation System, RNS, NeuroPace, Inc.
Page  745: Table   8 - describes the MRI-related information for one such system, the Freedom-8A
Page  745: Table   6 - Proclaim XR Recharge-Free Spinal Cord Stimulation (SCS) System, Abbott.
Page  746: Table   7 - Precision Montage MRI Spinal Cord Stimulator (SCS) System, Model SC-1200,
Page  747: Table   9 - summarizes the MRI-related information for the Nalu Neurostimula-
Page  747: Table   8 - Freedom-8A (FR8A) Stimulator Receiver for Spinal Cord Stimulator (SCS),
Page  748: Table   9 - Nalu Neurostimulation System for Peripheral Nerve Stimulation (PNS), Nalu
Page  749: Table  12 - 732
Page  750: Table  10 - Interstim II Sacral Nerve Stimulation System, Medtronic, Inc.
Page  751: Table  11 - Axonics Sacral Nerve Stimulation (SNM) Neurostimulator, Axonics Modula-
Page  752: Table  12 - SenTiva Vagus Nerve Stimulation (VNS) System, Model 1000, LivaNova, Inc.
Page  756: Table  13 - HiRes Ultra 3D Cochlear Implant, Advanced Bionics, LLC.
Page  757: Table  14 - Mi1200 SYNCHRONY Cochlear Implant, MED-EL Corporation.
Page  759: Table  15 - Prometra II Programmable Pump, Flowonix Medical.
Page  759: Table  16 - SynchroMed II Implantable Drug Infusion Pump, Model 8637, Medtronic, Inc.
Page  769: Table   1 - Basic policies and procedures for a hospital or medical center. This table provides a list of
Page  770: Table   1 - Continued
Page  782: Table   1 - lists safety concerns relevant to all medical imaging proce-
Page  783: Table   1 - Safety requirements shared by all diagnostic imaging modalities.
Page  784: Table   1 - (Continued) Safety requirements shared by all diagnostic imaging modalities.
Page  785: Table   2 - Responsibilities of the management team.
Page  785: Table   3 - Responsibilities of the MRI Safety Committee.
Page  785: Table   4 - Responsibilities of the MR Safety Officer.
Page  785: Table   5 - Responsibilities of employees.
Page  786: Table   6 - Determination of the appropriateness of the requested examination should be performed
Page  786: Table   6 - Examination ordering requirements for outpatient MRI services.
Page  789: Table   7 - outlines the indications for performing MRI
Page  789: Table   7 - Documentation required when managing pregnant patients referred for MRI.
Page  792: Table   8 - lists screening ques-
Page  792: Table   8 - Screening questions for determining risk for nephrogenic systemic fibrosis
Page  890: Table   1 - Static magnetic field limits for occupational exposure. All values are peak lev-
Page  891: Table   1 - The ICNIRP has a 2-T limit
Page  893: Table   3 - Induced
Page  893: Table   4 - summarizes the results from various studies. The average instan-
Page  894: Table   3 - RF limits for occupational exposure as applicable to MRI.  All time-averaged
Page  895: Table   4 - Personal dosimetry measurements from MRI workers.
Page  896: Table   5 - shows peak B, dB/dt and per-
Page  896: Table   5 - does not support this assertion.
Page  898: Table   6 - summarize these results and those from other studies (24-28, 30,
Page  898: Table   5 - Static magnetic field (B0) and magnetic fringe field values and percent (%) limit
Page  901: Table   6 - Peak static magnetic field (B), dB/dt and average RF field (B1) for various activ-
Page  931: Table   1 - A simple risk assessment matrix. Performance of risk assessments in all workplaces, including MRI
Page  933: Table   2 - They apply
Page  933: Table   2 - Exposure limits for patients and MRI workers according to the IEC standard 60601-2-33.
Page  935: Table   3 - summarizes the ICNIRP basic restrictions for workers, insofar as they are rel-
Page  935: Table   4 - summarizes the ICNIRP guidance on exposure limits for MRI patients. In its
Page  935: Table   3 - ICNIRP basic restrictions for occupational exposure to electromagnetic fields relevant to MRI.
Page  936: Table   3 - THE EU EMF DIRECTIVE
Page  936: Table   4 - ICNIRP recommended limits for patient exposures during MRI.
Page  944: Table   1 - The levels cited in the safety code were never meant to
Page  945: Table   1 - 1987 Health Canada safety code 26 patient exposure limits.
Page  947: Table   2 - shows the SAR limits for vol-
Page  947: Table   3 - shows the SAR limits for local
Page  948: Table   4 - outline the temperature
Page  948: Table   2 - SAR limits for volume transmit RF coils.
Page  948: Table   3 - Canadian SAR limits for local transmit RF coils.
Page  949: Table   4 - Canadian temperature limits for different operation modes of the MR system.
Page  996: Table   1 - Key Australian exposure limits for MRI. *
